Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Subcutaneous,Topical,Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Malaysia | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20251708 | N/A |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |